Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal Cancer

ABSTRACT: Interventions: cetuximab S-1 combination therapy cetuximab : Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) S-1 : 60 or 80 mg/m2/2weeks/day1-14, 4weeks Primary outcome(s): To determine the recomend dose of cetuximab and S-1 combinaton therapy Study Design: Single arm Non-randomized

DISEASE(S): Advanced/recurrent Colorectal Cancer

PROVIDER: 2619576 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II clinical trial of Cetuximab with Fluorouracil therapy for patients refractory or intolerable to Oxaliplatin and Irinotecan with KRAS wild-type unresectable/recurrent colorectal cancer

Project description:Interventions: (Cetuximab with Fluorouracil therapy) Cetuximab=400mg/m2 (day1)Cetuximab=250mg/m2/weekly(day 8-) with 1) l-LV=200mg/m2/bi-week 5-FU/bolus=400mg/m2/bi-week 5-FU/infusional=2,400mg/m2/bi-week (day1-3) 2) LV=75mg/day (*Administration for 4weeks and Drug withdrawal for one week)UFT=300-600mg/day* 3) Capecitabine=2,000mg/m2/day(*Administration for 2weeks and Drug withdrawal for one week) 4) S-1=80-120mg/day (*Administration for 2weeks and Drug withdrawal for one week) Primary outcome(s): Progression-free survival; PFS Study Design: Single arm Non-randomized

| 2623785 | ecrin-mdr-crc

Phase II Study of bi-weekly SOX+Cetuximab for EGFR positive and K-ras wild type dvanced and recurrent Colorectal Cancer

Project description:Interventions: Oxaliplatin:85mg/m2/week iv, day1.15 q 4weeks Cetuximab:day1 400, day8 250, day15 500mg/m2, day15- q 2weeks S-1:80mg/m2, day1-14 q 4weeks Primary outcome(s): Response ratte : RR Study Design: Single arm Non-randomized

| 2621320 | ecrin-mdr-crc

Multicenter Phase II Study of FOLFIRI and biweekly Cetuximab combination chemotherapy as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer. ( FIRBIC )

Project description:Interventions: Cetuximab 500 mg/m2/every 2weeks (day1) CPT-11 100 or 150 mg/m2 every 2weeks (day1) l-LV 200 mg/m2/every 2weeks (day1) 5-FU/bolus 400 mg/m2/every 2weeks bolus (day1) 5-FU/infusional 2,400 mg/m2/every 2weeks (day 1-3) Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622241 | ecrin-mdr-crc

Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer

Project description:Interventions: Capecitabine+oxaliplatin(XELOX)+Cetuximab Cetuximab loading dose 400mg/m2, 250mg/m2/week or 500mg/m2/2weeks Capecitabine 2000mg/m2(day1-7)/2weeks Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2622614 | ecrin-mdr-crc

Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 150mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized

| 2619160 | ecrin-mdr-crc

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

Project description:Interventions: S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622216 | ecrin-mdr-crc

Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 and 8 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 80mg/m2, day1,8 Primary outcome(s): 1) Phase I study To determine the maximum tolerated dose (MTD) and recommended dose (RD) 2) Phase II study Response rate Study Design: Single arm Non-randomized

| 2618747 | ecrin-mdr-crc

Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).

Project description:Interventions: Cetuximab/S-1 combination therapy Cetuximab weekly administration 400 mg/m2(day1), 250mg/m2/week(except day1) S-1 80-120mg/day, PO from day1 to day 28 of each 42 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2617952 | ecrin-mdr-crc

2weeks_vs_4weeks

Project description:Series of 6 repetitions of hybridization of treatment (2weeks) and control (4weeks) each. Comparison of 2 weeks old plants versus 4 weeks old plants. Keywords: repeat sample

2005-01-01 | GSE1198 | GEO

Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)

Project description:Interventions: L-OHP 130mg/m2 i.v. (day1) Cmab 250mg/m2 i.v. (only the first time Cmab 400mg/m2) S-1 80mg/m2 (day1-14) to be repeated every 3 weeks for 4 cycles. Surgery was planned after SOX+Cetuximab therapy. Primary outcome(s): Liver resection rate Study Design: Single arm Non-randomized

| 2619781 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data